Home > Annual Financials > BAL PHARMA

BAL PHARMA Financial Statement Analysis
[BOM: 524824|NSE : BALPHARMA]

The Revenues of BAL PHARMA have increased by 8.18% YoY .
The Earnings Per Share (EPS) of BAL PHARMA has decreased by -56.73 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

BAL PHARMA Last 5 Annual Financial Results
[BOM: 524824|NSE : BALPHARMA]

ConsolidatedMar2023
Mar2022
Mar2021
Mar2020
Mar2019
Revenues ₹304 Cr₹281 Cr₹251 Cr₹171 Cr₹225 Cr
Expenses ₹279 Cr₹257 Cr₹226 Cr₹166 Cr₹207 Cr
Operating Profit (Excl OI) ₹25 Cr₹24 Cr₹25 Cr₹5.03 Cr₹18 Cr
Other Income ₹0.94 Cr₹5.15 Cr₹1.14 Cr₹1.85 Cr₹1.01 Cr
Interest ₹12 Cr₹11 Cr₹12 Cr₹13 Cr₹13 Cr
Depreciation ₹9.13 Cr₹9.04 Cr₹9.52 Cr₹7.68 Cr₹6.16 Cr
Profit Before Tax ₹4.75 Cr₹9.18 Cr₹4.10 Cr₹-14 Cr₹-0.20 Cr
Profit After Tax ₹2.62 Cr₹5.71 Cr₹4.71 Cr₹-13 Cr₹2.15 Cr
Consolidated Net Profit ₹2.57 Cr₹5.61 Cr₹4.74 Cr₹-12 Cr₹3.79 Cr
Earnings Per Share (Rs)₹1.64₹3.79₹3.20₹-8.62₹2.67
PAT Margin (%)0.862.031.88-7.530.96
ROE(%)4.3110.348.97-21.653.27
ROCE(%)9.5612.339.72-0.446.88
Total Debt/Equity(x)2.051.802.092.261.85

Key Financials

Market Cap : ₹ 155.8 Cr
Revenue (TTM) : ₹ 327.0 Cr
Net Profit(TTM) : ₹ 3.5 Cr
EPS (TTM) : ₹ 2.2
P/E (TTM) : 44.1

Industry Peers & Returns1W1M1Y
BAL PHARMA -0.5% -1.3% 25.1%
SUN PHARMACEUTICAL INDUSTRIES 0.9% -6.6% 58.8%
CIPLA -1% -5.6% 54.6%
DR REDDYS LABORATORIES 0.9% 2.2% 27.3%
ZYDUS LIFESCIENCES 2.8% -0.6% 96.2%
DIVIS LABORATORIES -2.2% 6.2% 21.2%
MANKIND PHARMA -6.3% -5% NA
TORRENT PHARMACEUTICALS -0.9% 1.1% 64.2%
LUPIN -2.1% 0.4% 137.2%


BAL PHARMA Revenues
[BOM: 524824|NSE : BALPHARMA]

Y-o-Y

8.18 %

5 Yr CAGR

7.83 %

Years Revenues % Change
Mar2023 ₹304 Cr
8.18
Mar2022 ₹281 Cr
12.25
Mar2021 ₹251 Cr
46.43
Mar2020 ₹171 Cr
-23.96
Mar2019 ₹225 Cr -


BAL PHARMA Operating Profit
[BOM: 524824|NSE : BALPHARMA]

Y-o-Y

5.30 %

5 Yr CAGR

9.31 %

Years Operating Profit % Change
Mar2023 ₹25 Cr
5.30
Mar2022 ₹24 Cr
-2.70
Mar2021 ₹25 Cr
390.23
Mar2020 ₹5.03 Cr
-71.57
Mar2019 ₹18 Cr -

Operating Margins
Y-o-Y

-2.70 %

5 Yr CAGR

1.37 %

Years Operating Margin% % Change
Mar2023 8.3%
-2.70
Mar2022 8.53%
-13.31
Mar2021 9.84%
234.69
Mar2020 2.94%
-62.60
Mar2019 7.86% -

BAL PHARMA Profit After Tax
[BOM: 524824|NSE : BALPHARMA]

Y-o-Y

-54.17 %

5 Yr CAGR

-9.23 %

Years Profit After Tax % Change
Mar2023 ₹2.57 Cr
-54.17
Mar2022 ₹5.61 Cr
18.35
Mar2021 ₹4.74 Cr
Positive
Mar2020 ₹-12 Cr
Negative
Mar2019 ₹3.79 Cr -

PAT Margins
Y-o-Y

-57.64 %

5 Yr CAGR

-2.71 %

Years PAT Margin(%) % Change
Mar2023 0.86 %
-57.64
Mar2022 2.03 %
7.98
Mar2021 1.88 %
Positive
Mar2020 -7.53 %
Negative
Mar2019 0.96 % -

BAL PHARMA Earnings Per Share (EPS)
[BOM: 524824|NSE : BALPHARMA]

Y-o-Y

-56.73 %

5 Yr CAGR

-11.47 %

Years EPS % Change
Mar2023 ₹1.64
-56.73
Mar2022 ₹3.79
18.44
Mar2021 ₹3.20
Positive
Mar2020 ₹-8.62
Negative
Mar2019 ₹2.67 -

BAL PHARMA Return on Capital Employed (ROCE)
[BOM: 524824|NSE : BALPHARMA]

Y-o-Y

-22.47 %

5 Yr CAGR

8.57 %

Years ROCE % Change
Mar2023 9.56%
-22.47
Mar2022 12.33%
26.85
Mar2021 9.72%
Positive
Mar2020 -0.44%
Negative
Mar2019 6.88% -

BAL PHARMA Share Price vs Sensex

Current Share Price : ₹98.6
Current MarketCap: ₹ 155.8 Cr
Updated EOD on :May 07,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
BAL PHARMA

-0.5%

-1.3%

25.1%

SENSEX

-1.6%

-0.5%

19.8%

BAL PHARMA related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about BAL PHARMA Financials


How the annual revenues of BAL PHARMA have changed ?

The Revenues of BAL PHARMA have increased by 8.18% YoY .

How the Earnings per Share (EPS) of BAL PHARMA have changed?

The Earnings Per Share (EPS) of BAL PHARMA has decreased by -56.73 % YoY .